A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS clinical trials group study 323/mycoses study group study 40

Clinical Infectious Diseases

Volumn 41, Issue 10, 2005, Pages 1473-1480

  Goldman, Mitchell ^a   Cloud, Gretchen A ^b   Wade, Karen D ^b   Reboli, Annette C ^b   Fichtenbaum, Carl J ^b   Hafner, Richard ^b   Sobel, Jack D ^b   Powderly, William G ^b   Patterson, Thomas F ^b   Wheat, Lawrence J ^b   Stein, David K ^b   Dismukes, William E ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FLUCONAZOLE; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INTERMITTENT THERAPY; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; OROPHARYNX; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 27644449638     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/497373     Document Type: Article

References (26)

1. Phelan JA, Saltzman BR, Friedland GH, Klein RS. Oral findings in patients with acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol 1987; 64:50-6.
2. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991; 5:519-25.
3. Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia JJ, et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 2000; 14:979-85.
4. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27:1291-4.
5. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543-9.
6. Kerdpon D, Pongsiriwet S, Pangsomboon K, et al. Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. Oral Diseases 2004; 10:138-44.
7. Chidzonga MM. HIV/AIDS orofacial lesions in 156 Zimbabwean patients at referral oral and maxillofacial surgical clinics. Oral Diseases 2003; 9:317-22.
8. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-8.
9. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Medicine 2004; 5:140-3.
10. Willocks L, Leen CL, Brettle RP, Urquhart D, Russell TB, Milne LJ. Fluconazole resistance in AIDS patients. J Antimicrob Chemother 1991; 28:937-9.
11. Sanguineti A, Carmichael JK, Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med 1993; 153:1122-4.
12. Smith D, Boag F, Midgley J, Gazzard B. Fluconazole resistant Candida in AIDS. J Infect 1991; 23:345-6.
13. Heinic GS, Stevens DA, Greenspan D, et al. Fluconazole-resistant Candida in AIDS patients: report of two cases. Oral Surg Oral Med Oral Pathol 1993; 76:711-5.
14. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994; 19:684-6.
15. Barchiesi F, Hollis RJ, Del Poeta M, et al. Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Clin Infect Dis 1995; 21:561-4.
16. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993; 17:1018-21.
17. Revankar SG, Dib OP, Kirkpatrick WR, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26:960-3.
18. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219-25.
19. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30:749-56.
20. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. Wayne, PA: NCCLS, 1997.
21. Revankar SG, Kirkpatrick WR, McAtee RK, et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med 1998; 105:7-11.
22. Pagani J-L, Chave J-P, Casjka C, Glauser M-P, Bille J. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 2002; 50:231-40.
23. Bradbury BD, Jick SS. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 2002; 22:697-700.
24. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex: randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991; 151:2458-64.
25. Manfredi R, Mastroianni A, Coronado OV, Chiodo F. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch Intern Med 1997; 157:64-9.
26. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with dotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:700-5.